Black Diamond Therapeutics Inc

Research Black Diamond Therapeutics Inc (BDTX) on Bullrun: market cap USD 100.28M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBDTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 100.28M
• Financial periodFY2025
• RevenueUSD 70.00M
• Net incomeUSD 22.37B

Valuation Snapshot

latest market cap is USD 100.28M.

About Black Diamond Therapeutics Inc

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.

Frequently asked questions

What is Black Diamond Therapeutics Inc's market cap?

Black Diamond Therapeutics Inc's market capitalization is USD 100.28M.

What does Black Diamond Therapeutics Inc do?

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.